Hologic

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Hologic
Public
Traded as
Industry Medical products
Founded 1985
Headquarters Marlborough, Massachusetts, U.S.
Key people
Stephen P. MacMillan
President and CEO
Revenue US$ 2.83 billion (2016)
US$ 0.5 billion (2016)
US$ 0.3 billion (2016)
Number of employees
~5,300
Website www.hologic.com

Hologic, Inc. is a medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. The Company’s core business units focus on diagnostics, breast health, gynecological surgical, skeletal health, and medical aesthetics. Its major products include the Selenia Dimension mammography system, the Discovery and Horizon bone densitometers, the NovaSure endometrial ablation device, the ThinPrep pap test, and the Aptima, Cervista, and Prodesse diagnostic assays. While historically the Company was focused on women's health, expansion into the molecular diagnostics space has resulted in the Company's rebranding from "The Women's Health Company" to its current tagline, "The Science of Sure".

Recent Mergers and Acquisitions[edit]

On May 20, 2007, Hologic announced a merger (via a cash and stock transaction) with the Cytyc Corporation to create a $10 billion women's healthcare company with over $1 billion in projected annual sales.[1]

On April 30, 2012, Hologic announced a merger with Gen-Probe for about $3.72 billion by cash.

On February 14, 2017, it was announced that Hologic had acquired Cynosure, Inc., a leading manufacturer and distributor of aesthetic medical devices. The transaction was completed on March 22, 2017.[2]

Infiltration by Carl Icahn[edit]

In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the Company's board of directors, two additional directors backed by Mr. Icahn were added to the board, each managing directors of Icahn holding companies.[3] The directors relinquished their positions in March 2016; by April 2016, Icahn's share in the Company had fallen below 5%.[4]

References[edit]

  1. ^ https://web.archive.org/web/20070527064309/http://www.forbes.com/feeds/ap/2007/05/21/ap3740939.html. Archived from the original on May 27, 2007.  Missing or empty |title= (help)
  2. ^ Inc., Hologic,. "Hologic Completes Acquisition of Cynosure". www.prnewswire.com. Retrieved 2017-03-25. 
  3. ^ "Hologic names new CEO, adds two Icahn nominees to board". Reuters.com. December 9, 2013. 
  4. ^ "Carl Icahn Cuts Hologic (HOLX) Stake Below 5%". StreetInsider.com. April 13, 2016. 

External links[edit]